Compare Novavax Inc (NVAX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Raymond James Financial, Inc. — how do they compare? Novavax Inc trades at $9.86 (market cap $1.68B), while Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B). The key difference: Raymond James Financial, Inc. is far larger — about 20.2× Novavax Inc's market cap, and Raymond James Financial, Inc. pays a 1.22% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RJF | |
|---|---|---|
Market Cap | $1.68B | $33.96B |
Sector | Health | Financials |
52-Week High | $11.19 | $181.18 |
52-Week Low | $6.22 | $140.89 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a mixed technical picture showing bearish overall signals but bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $3.14 beating estimates of $2.93, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Recent developments include dividend declarations and PGA TOUR sponsorship announcements.
RJF presents a balanced investment case with 44% analyst buy ratings and a $184.11 consensus price target offering 4.3% upside. Strengths include consistent earnings growth and wealth management expansion, while risks involve rising expenses and capital market volatility. The stock trades at reasonable valuations with P/E of 15.39 and P/S of 2.36, supported by 15.37% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
